Focus Day
Tuesday, August 29
Reviewing Mechanisms of Resistance
9.00
Reviewing the Intrinsic Mechanisms of Resistance to Cell Therapy
Sid Kerkar, Vice President, R&D, EXUMA Biotechnology
9.30
Roundtable Discussion: Discussing Mechanisms of Resistance & How to Overcome Them
John Rossi, Vice President, Head of, Translational Medicine, CARGO Therapeutics
Renaud Vaillant, Founder & Chief Executive Officer, Alaya.bio
Leveraging Innate Immune Cells to Overcome the Tumor Microenvironment
11:00
Overcoming Resistance & the Tumor Microenvironment with CAR-Macrophage Therapies
Sumiti Jain, Vice President, Head of R&D, Inceptor Bio
11:30
Leveraging NKT Cells to Tackle the Tumor Microenvironment
Jason Damiano, Chief Scientific Officer, Appia Bio
Developing Next-Generation CAR-T Therapies to Overcome Mechanisms of Resistance
1:00
Strategies to Deliver Best-in-Class Engineered CAR-T Cell Products to Overcome Resistance & Address Barriers to Patient Access
John Rossi, Vice President, Head of Translational Medicine, CARGO Therapeutics
1:30
Targeting Solid Tumors with SMART CAR-T by Overcoming Suppressive Tumor Microenvironment
LJ Shen, Senior Vice President, Head of R&D, Gracell Biotechnologies
2:00
Overcoming the Challenges of CAR-T in Solid Tumors
Hong Ma, Senior Vice President, Clinical Development, CARsgen Therapeutics
Developing Next-Generation TIL Therapies to Overcome Mechanisms Resistance
3:00
Next-Gen TIL: Counteracting the Solid Tumor Microenvironment
Michelle Simpson Abelson, Executive Director, Research, Iovance Biotherapeutics
3:30
Developing Gene-Edited TIL Cell Therapy Products to Revolutionize the Treatment of Solid Tumors
Karrie Wong, Senior Director, Head of Cell Therapy, KSQ Therapeutics
4:10
Discussing Diversity at CAR-TCR
“Good place to connect to the heartbeat and trends of the cell and gene therapy industry. There were a lot of industry leaders, knowledgeable speakers, helpful vendors, and a good focus to the content.”
Stephen Crimlisk, Manager, MSAT, BioNTech, Past Attendee